Praxis, holding about $1.3bn, faces back-to-back FDA verdicts on two drugs

Praxis Precision Medicines says it has about $1.3bn in cash, enough to fund operations into 2028. The company disclosed this on 9 November 2026 with its third-quarter results. That cushion covers the period in which the FDA is due to rule on two of its new drug applications.

The first ruling concerns relutrigine, which is under review for developmental and epileptic encephalopathies linked to SCN2A and SCN8A. The agency's goal date for that application is 27 December 2026. The second is ulixacaltamide for essential tremor, with a goal date of 29 January 2027. These goal dates are set under the Prescription Drug User Fee Act, and they mark when the FDA aims to finish its review. The agency can miss them or extend them, and an aim is not a guarantee of approval.

Between now and the first decision, Praxis expects topline results from its EMERALD study in the fourth quarter of 2026. The company has also scheduled an Investor Day for 12 November. The source material gives no detail on what either event will cover, so the content of the data and the presentation remains to be seen.

The update does not address pricing, launch timing or sales expectations for either product, so any commercial picture will have to wait for the company's own disclosures or for regulatory outcomes.